The development of proteinase-activated receptor-2 modulators and the challenges involved

Protease-activated receptor-2 (PAR2) has been extensively studied since its discovery in the mid-1990. Despite the advances in understanding PAR2 pharmacology, it has taken almost 25 years for the first inhibitor to reach clinical trials, and so far, no PAR2 antagonist has been approved for human us...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Biochemical Society transactions 2020-12, Vol.48 (6), p.2525-2537
Hauptverfasser:	McIntosh, Kathryn A, Cunningham, Margaret R, Bushell, Trevor, Plevin, Robin
Format:	Artikel
Sprache:	eng
Schlagworte:	Immunology & Inflammation Pharmacology & Toxicology Review Signaling
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!